Mean plasma 1 a ,25-dihydroxyvitamin D[1 a ,25(OH) 2 D] was significantly increased and serum parathyroid hormone was suppressed in three patients with sarcoidosis and hypercalcemia. Prednisone lowered the mean plasma 1 a ,25(OH) 2 D to normal range and corrected the hypercalcemia. To elucidate the mechanism for the increased sensitivity to vitamin D in this disorder, the effects of orally-administered vitamin D 2 were determined in seven normal subjects, four patients with sarcoidosis and normal calcium metabolism and three patients with sarcoidosis and a history of hypercalcemia who were normocalcemic when studied. Serum and urinary calcium, serum 25-hydroxyvitamin D (25-OHD), plasma 1 a ,25(OH) 2 D and, in some studies, calcium balance were measured. Vitamin D 2 , 250 µg a day for 12 d, produced little, if any, change in mean plasma 1 a ,25(OH) 2 D and in urinary calcium in the normals and in the patients with normal calcium metabolism. In contrast, vitamin D 2 produced increases in plasma 1 a ,25(OH) 2 D from concentrations which were within the normal range (20-55 pg/ml) to abnormal values and increased urinary calcium in two patients with abnormal calcium metabolism. In an abbreviated study in the third patient, vitamin D 2 , 250 µg a day for 4 d, also increased plasma 1 a ,25(OH) 2 D abnormally from a normal value. There was a highly significant correlation between plasma 1 a ,25(OH) 2 D and urinary calcium. Serum 25-OHD and serum calcium remained within the normal range in all subjects and patients. These […]
correlation between plasma 1,,25(OH)2D and urinary calcium. Serum 25-OHD and serum calcium remained within the normal range in all subjects and patients. These findings provide evidence that the defect in calcium metabolism in sarcoidosis probably results from impaired regulation of the production and(or) degrada-
INTRODUCTION
Abnormal calcium metabolism in sarcoidosis is characterized by enhanced intestinal absorption of the ion and hypercalciuria with or without hypercalcemia, which may be associated with renal stones, nephrocalcinosis, and impaired renal function (1) (2) (3) (4) (5) (6) (7) (8) . Patients with sarcoidosis exhibit increased sensitivity to small doses of vitamin D, which are ineffective in normal subjects (1, (4) (5) (6) . The observation that serum antirachitic activity has been shown to be within the normal range (3, 5) has led to the conclusion that the abnormal calcium metabolism in sarcoidosis results not from hypervitaminosis D but from increased sensitivity to vitamin D (3, 5) .
It is known that vitamin D is converted by the liver to 25-hydroxyvitamin D (25-OHD)l (9) , which in turn undergoes L,Q-hydroxylation by the kidney to form 1a, 25- dihydroxyvitamin D (a1,25(OH)2D) (10, 11) , the most potent metabolite of the vitamin that augments the intestinal absorption of calcium (11) and stimulates bone resorption (12) .
The mechanism for the abnormal sensitivity to vitamin D in sarcoidosis has not been determined. In the present work evidence is presented that the defect in calcium metabolism results from increases in circulating lcg,25(OH)2D. ' Abbreviations used in this paper: PTH, parathyroid hormone; 25-OHD, 25-hydroxyvitamin D; 1.,25(OH)2D, 1,,,25dihydroxyvitamin D. TheJournal of Clinical Investigation Volume 64 July 1979-218-225 218 METHODS Eight normal adult men ranging in age from 20 to 70 yr and eight patients with sarcoidosis, four men and four women ranging in age from 24 to 63 yr, were studied. They were hospitalized on the Clinical Research Center of the Indiana University Medical School and were given a constant daily diet and fluid intake. Fasting serum samples were collected at intervals of 4 d and were analyzed for calcium (13) , 25 -OHD and parathyroid hormone (PTH). Plasma was also obtained for 1,,25(OH)2D. 24-h urine collections and, in some studies, 4-d fecal pools were obtained. Diet, urine, and stools were analyzed for calcium (13) . Vitamin D2 (Winthrop Laboratories, New York) in propylene glycol was given daily as a single oral dose. 1e,25(OH)2D3, synthesized by methods previously reported (14) , was made up as a sterile solution in propylene glycol. It was given as a single intravenous or oral moming dose. Three patients were studied both while hospitalized at the Indiana University Hospital and as outpatients. In these individuals, fasting samples were obtained for creatinine as well as for calcium, PTH, 25-OHD, and l,,25(OH)2D. Serum creatinine was measured by AutoAnalyzer (Technicon Instruments Corp., Tarrytown, N. Y.). Serum 25-OHD was measured by a competitive serum protein-binding method (15) ; in most instances, values were obtained after chromatography on Sephadex LH-20 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) (16) . In our laboratory the normal range without prior chromatography is from 10 to 80 ng/ml and with chromatography is from 8 to 61 ng/ml. Results obtained without chromatography are so noted in the text. Plasma 1e,25(OH)2D was measured by bioassay as previously described (17, 18) . Samples were either extracted with dichloromethane and chromatographed on Sephadex LH-20 in the solvent system Skellysolve B (Skelly Oil Co., Tulsa, Okla.):chloroform:methanol (9:1:1) or with benzene, which was then washed with 0.1 M phosphate buffer, pH 10.5 (17) . Most of the samples were processed by the latter method. The extracts were then further fractionated by high pressure liquid chromatography on ,uPorosil (Waters Associates, Inc., Milford, Mass.) with the solvent system 13% isopropanol in n-hexane.
In this sytem 1a,25(OH)2D2 elutes with la,25(OH)2D3 (17) (18) (19) . The fractions that contained both metabolites were collected. Recovery was determined by addition to the serum of [26,27-3H] lc,,25(OH)2D3. Ie,,25(OH)2D was then measured by release of 45Ca from fetal rat bones in organ culture (17, 18) . Each serum sample was assayed at two dilutions and the value for each sample and standard was the mean of four or six replicate samples (18) . Because in this system I.,25(OH)2D2 and 1,,l,25(OH)2D3 are equipotent in causing release of 45Ca (20) , and because fractions that contained both metabolites were collected, the assay measures the total amount of 1,a,25(OH)2D. The mean value in normal subjects is 33±2 pg/ml and range is 20 to 55 pg/ml (n = 16).
The 95% confidence values (mean±2 SD) are 18 to 48 pg/ml. The interassay variation is 9.1% (n = 17).
In several studies plasma was assayed for lc,,25(OH)2D in patients during treatment with prednisone. Samples were obtained 8 or more h after the last dose of the steroid. In view of the known effects of steroids to inhibit bone resorption in this assay system (21) and the demonstration that prednisone is rapidly converted to prednisolone in man (22, 23) , additional studies were carried out. Both steroids were clearly separated from 1,,,25(OH)2D during high pressure liquid chromatography in the system described above. It was also demonstrated that an extract of plasma from one of the patients given prednisone did not inhibit the release of 45Ca produced by added 1l,,25(OH)2D in cultured rat bones. Serum PTH was measured by radioimmunoassay as pre-viously described (24, 25) with two antisera, which predominately measure the carboxy-terminal portion of the molecule. In the first assay, antiserum from chicken No. 9 (kindly supplied by Dr. E. Slatopolsky, Washington University School of Medicine, St. Louis, Mo.) was used at a final concentration of 1:20,000 and highly purified bovine PTH (Inolex Corp., Biomedical Div., Glenwood, Ill.; lot 155258, 971 U/mg) was the standard. Serum PTH is detectable in 85% of normal subjects and the normal range is from undetectable (<150 pg/ml) to 550 pg/ml (24, 25) . In the second assay, antiserum from chicken 77125 developed in this laboratory was employed at a final concentration of 1:10,000 and highly purified bovine PTH (Inolex Corp.; lot 1508 D003, 867 U/mg) was the standard. Serum PTH is detectable in over 98% of normal subjects and the normal range is from undetectable (<100 pg/ml) to 540 pg/ml (n = 66).2 The intraassay and interassay variations are 12 and 16.7%, respectively.
Student's t test was used to determine the significance of differences of paired or unpaired samples. Correlation coefficient and Student's t test were carried out with a Hewlett-Packard calculator (model 9810A, Hewlett-Packard Co., Palo Alto, Calif.).
RESULTS
Eight ofthe nine patients had the diagnosis of sarcoidosis confirmed histologically (Table I) . Patient B, who had never had a biopsy, had a history of hypercalcemia, granulomatous disease on chest x ray, and a negative skin test for tuberculosis. Five of the other patients also had a history of hypercalcemia and one ofthese had had kidney stones.
Three patients had hypercalcemia, one of them on two separate occasions (Table II) . Serum PTH was either undetectable (patients G and H) or in the low normal range (patient I). Plasma 1,,n,25(OH)2D, determined in two samples in each patient, was either elevated or in the upper range of normal. Mean plasma 1,,25(OH)2D was 62+6 pg/ml in these patients, a value significantly higher (P < 0.001) than that of 33±2 pg/ml obtained in normal adult subjects (n = 16) and was reduced significantly by prednisone to 26±4 pglml (P <0.02). Prednisone lowered the mean serum calcium from 13 .3±0.5 to 9.7±0.1 mg/dl (P < 0.01). Serum 25-OHD was abnormally increased in patient G who had had exposure to sunlight while playing golf during the summer (he denied having taken vitamin D) and it remained elevated after treatment with prednisone. Serum creatinine was increased with hypercalcemia in each ofthe patients and was lowered after correction of the hypercalcemia by prednisone (Table II) . In patient H, renal function was severely impaired and improved substantially with treatment.
In view ofthe known abnormal sensitivity to vitamin D of patients with sarcoidosis (1, (4) (5) (6) , the effects of vitamin D2, 250 ,ug(10,000 IU)/d for 12 d, were compared in seven normal subjects and in seven patients with sarcoid and a normal serum calcium.
In the normal subjects and patients with normal calcium metabolism, vitamin D2 produced very little change in mean plasma 1,,25(OH)2D, which remained within the normal range (Table III) , or mean serum and urinary calcium (Table IV) . Mean serum 25-OHD remained within the normal range in both the normals and patients (Table III) . Whereas the increases in mean plasma 1,,25(OH)2D and mean urinary calcium were statistically significant (P < 0.05) in the four patients, the actual differences were quite modest, averaging 14 and 21%, respectively.
Three patients (including patient G) previously had had hypercalcemia and had been treated with prednisone so that at the time of study their serum calcium was normal. The interval after the last dose of steroid ranged from 3 d in patient F (who had received a 4-d course) to over 1 yr in patient E. Patient G had received prednisone, 5 mg every other day for 6 mo, at the time of evaluation. The drug was not given during the study.
In patient E (Fig. 1) , vitamin D2 increased serum 25- Fecal calcium decreased during vitamin D2 and serum calcium remained within the normal range. In patient F (Fig. 2) , vitamin D2 increased plasma 1<,t,25(OH)2D from 23 pg/ml (day 1) to as high as 132 pg/ml (day 9). Serum 25-OHD remained within the normal range. Mean urinary calcium increased from 287±9 mg/d (days 1-4) to 406+31 mg/d (days 9 through 13, P < 0.05). Serum calcium remained normal and fecal calcium did not change. In patient G (Fig. 3) , vitamin D2 given for only 4 d increased plasma 1a:,25(OH)2D3 from 33 pg/ml (day 1) to 86 pg/ml (day 5). Serum 25-OHD was 26 ng/ml (day 1) and 21 ng/ml (day 5). Serum and urinary calcium stayed within the normal range. Thus, in three of the patients who had had hypercalcemia, vitamin D2 increased plasma 1,,,25(OH)2D from values that were within the normal range to values that were clearly abnormally elevated. Serum 
DISCUSSION
Three patients were studied when hypercalcemic and showed suppression of serum PTH and significant increases in mean plasma 1,,25(OH)2D. Prednisone lowered the mean plasma 1of,25(OH)2D significantly and corrected the hypercalcemia and serum PTH returned to the normal range. Cushard et al. (26) also observed suppression of serum PTH in six patients with sarcoidosis and hypercalcemia and the return of serum PTH to normal after correction of the hypercalcemia with prednisone.
PTH appears to be a major regulator of the renal production of 1,a,25(OH)2D in man; plasma values for the metabolite are increased in primary hyperparathyroidism and decreased in hypoparathyroidism (27) (28) (29) . The findings of increased plasma 1a,25(OH)2D despite functional hypoparathyroidism in the patients with hypercalcemia are all the more striking in view ofthese considerations. They suggest that plasma la,25(OH)2D
in patients with sarcoidosis and abnormal calcium metabolism is regulated by factors other than PTH. Whereas vitamin D in modest doses did not alter the calcium metabolism or plasma 1a,25(OH)2D in the normals or patients with normal calcium metabolism, it increased plasma 1<X,25(OH)2D and urinary calcium abnormally in the patients with a history of hypercalcemia without increasing their serum calcium. This lack of hypercalcemia is attributed to the low calcium patient and always preceded the increases in urinary calcium.
There was no correlation between serum calcium and plasma 1<,,25(OH)2D in the patients either in the presence or absence of hypercalcemia. However, there was a highly significant correlation between plasma 1,,25(OH)2D and urinary calcium in the normals and patients given vitamin D (Fig. 4) . The correlation was also significant for the patients with or without abnormal calcium metabolism (r = 0.713, P < 0.01) as well as for the patients with abnormal calcium metabolism alone (r = 0.772, P < 0.01).
Studies were carried out to compare the effects of 1,,25(OH)2D3 on serum and urinary calcium in normal subjects and patients to those produced in the patients by endogenous 1,,25(OH)2D (Table V) . la,25(OH)2D3, given at doses of 1, 2, and 4 ,ug/d for 4 d at each dose, produced marked increases in urinary calcium in both the normal subjects and patients but did not increase the serum calcium abnormally. The changes were comparable whether the 1,,25(OH)2D3 was given orally or intravenously. Thus, exogenously administered 1,,25(OH)2D3 produced increases in urinary calcium that were comparable to those produced by 1l,,25(OH)2D in the patients from endogenous sources and in the doses used did not produce hypercalcemia. I la,25(OH)2D3 was given daily as follows: 1 ,ug (days 5-8), 2 ,tg (days 9-12), and 4 ,ug (days 13-16). § l1c,25(OH)2D3 was given intravenously in these subjects and orally to the others.
intake (see below) in view of reports that show that serum calcium may vary with dietary intake of the ion in sarcoidosis (1, 4, 5) . In similar studies, exogenously administered 1,e,25(OH)2D3 produced comparable increases in urinary calcium without causing hypercalcemia. In fact, our studies were carried out with a low calcium diet to prevent possible hypercalcemia and its consequences on renal function. Fractional intestinal absorption of calcium has been demonstrated to be increased in patients with sarcoid who have hypercalciuria and not hypercalcemia, and to correlate with urinary calcium (8) . In our studies, plasma 1,,25(OH)2D did not correlate with serum calcium either in the absence or presence of hypercalcemia but correlated strongly with urinary calcium. There are a number ofpossible reasons for this lack ofcorrelation. In primary hyperparathyroidism, another disorder characterized by increases in plasma 1,,l,25(OH)2D, intestinal absorption of calcium and urinary calcium, plasma 1et,25(OH)2D also has been shown to correlate significantly with the fractional intestional absorption ofcalcium and with urinary calcium but not with serum calcium even when the patients are given the same calcium intake and a substantial number of individuals are evaluated (28) . It is possible that variation in the ability of the kidneys of different patients to excrete an excess calcium load produced by increased circulating le,,25(OH)2D in these two disorders may obscure any net effect on serum calcium. In sarcoid, it is likely that hypercalcemia occurs when the compensatory ability of the kidneys to excrete the calcium load has been exceeded. As noted already, alteration ofserum calcium in sarcoid by changes in dietary intake has been shown in a number of studies (1, 4, 5) . The lack of control of calcium intake in our patients when they were hypercalcemic may be responsible in part for the lack of correlation between plasma la,25(0H)2D and serum calcium. Also, two of the patients had diminished renal function, one severely, which would impair the compensatory ability of the kidneys to excrete calcium. Also, 1n,25(OH)2D3 was shown to produce dose-related increases in urinary calcium without causing hypercalcemia in normal subjects and patients. Thus, in these studies there was no correlation between the dose of 1,,25(OH)2D3 and the serum calcium.
Increases in circulating 25-OHD and not 1.,25-(OH)2D are apparently responsible for hypercalcemia in vitamin D intoxication (30) . Serum 25-OHD was modestly increased in only one individual (patient G) with sarcoid and hypercalcemia. However, it was far below the range (500 ng/ml or above) reported in patients (30) and rats (31) with vitamin D intoxication. Serum 25-OHD was not increased abnormally in any of the other patients even after they were given vitamin D. Thus, the abnormal calcium metabolism in sarcoid cannot be attributed to this metabolite. 25 (OH)2D3 to a more polar, biologically inactive metabolite. We interpret our results to mean that prednisone acts in sarcoid by reducing the amount of la,25(OH)2D in the circulation. They do not exclude the possibility that prednisone may also inhibit the peripheral action of 1,,25(OH)2D (21) . Production of la,25(OH)2D is diminished in renal failure (27, 28) . We reported studies in a patient with sarcoid, hypercalcemia, hypercalciuria, and an increased sensitivity to vitamin D who developed transient nephritis (34) . Diminished intestinal absorption of calcium, hypocalcemia, and a lack of response to small doses of vitamin D occurred with the onset of renal disease. After recovery, there was recurrence of the changes in calcium metabolism characteristic of sarcoid. In this patient, the defect in vitamin D metabolism characteristic of renal failure was superimposed on the defect produced by sarcoid. The resulting changes in calcium metabolism may have resulted from changes in circulating la,25(OH)2D. The findings in this patient support the concept that renal production of 1,25(OH)2D may be important in the pathogenesis of the abnormal calcium metabolism in sarcoid.
In summary, the data presented provide a strong argument that increases in circulating 1,25(OH)2D account for the abnormal calcium metabolism in sarcoid. The evidence is as follows: (a) mean plasma 1a,25(OH)2D is significantly increased in patients with hypercalcemia who have suppression of serum PTH, (b) mean plasma la,25(OH)2D is brought into the normal range and hypercalcemia is corrected by prednisone, (c) vitamin D, in modest doses, markedly increases plasma 1<,,25(OH)2D and urinary calcium (which correlate with each other) in patients with abnormal calcium metabolism but has no effect in normal subjects or in patients with normal calcium metabolism, and (d) comparable dose-related increases in urinary calcium are produced by 1a,25(OH)2D3.
The modest but significant increases in the plasma 1,25(OH)2D and urinary calcium produced by vitamin D in the patients with "normal" calcium metabolism raises the possibility that these individuals might also exhibit abnormalities if challenged with larger doses of the vitamin. Additional studies are warranted to clarify this issue and to determine the cause for the abnormal metabolism of vitamin D in this disorder.
Finally, a number ofadult patients are being reported with (a) hypercalcemia, suppression ofserum PTH, and elevation of plasma 1,25(OH)2D, (b) no clinical evidence for sarcoidosis, and (c) reduction of plasma 1,,25(OH)2D and correction of hypercalcemia by prednisone (35) .3 It is possible that the mechanism for defective vitamin-D metabolism in these patients may be similar to that in sarcoid. In our view, these individuals may eventually be shown to fall into the category of an acquired form of idiopathic hypercalcemia, a disease more commonly found in infants and children and characterized by an abnormal sensitivity to vitamin D (36, 37) .
